JP2012524075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012524075A5 JP2012524075A5 JP2012505977A JP2012505977A JP2012524075A5 JP 2012524075 A5 JP2012524075 A5 JP 2012524075A5 JP 2012505977 A JP2012505977 A JP 2012505977A JP 2012505977 A JP2012505977 A JP 2012505977A JP 2012524075 A5 JP2012524075 A5 JP 2012524075A5
- Authority
- JP
- Japan
- Prior art keywords
- immunotherapy
- combination
- antigen
- composition
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 50
- 238000009169 immunotherapy Methods 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 230000001024 immunotherapeutic effect Effects 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 230000002163 immunogen Effects 0.000 claims 11
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 9
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 5
- 241000700662 Fowlpox virus Species 0.000 claims 4
- 241000700618 Vaccinia virus Species 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108010084313 CD58 Antigens Proteins 0.000 claims 2
- 102000006108 VHL Human genes 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 101150046474 Vhl gene Proteins 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- SNKUSVNHTCUELQ-UHFFFAOYSA-N 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic aci Chemical compound CC(C)CC(C(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(N)CC1=CC=C(O)C=C1 SNKUSVNHTCUELQ-UHFFFAOYSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 102100036526 Anoctamin-7 Human genes 0.000 claims 1
- 108010077333 CAP1-6D Proteins 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 108700037122 EWS-FLI fusion Proteins 0.000 claims 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 108010034145 Helminth Proteins Proteins 0.000 claims 1
- 101000928370 Homo sapiens Anoctamin-7 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 241000578472 Human endogenous retrovirus H Species 0.000 claims 1
- 241000192019 Human endogenous retrovirus K Species 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 108010008705 Mucin-2 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 102100030306 TBC1 domain family member 9 Human genes 0.000 claims 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 1
- 102000018252 Tumor Protein p73 Human genes 0.000 claims 1
- 108010091356 Tumor Protein p73 Proteins 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 244000078703 ectoparasite Species 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 244000000013 helminth Species 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- ONCZDRURRATYFI-QTCHDTBASA-N methyl (2z)-2-methoxyimino-2-[2-[[(e)-1-[3-(trifluoromethyl)phenyl]ethylideneamino]oxymethyl]phenyl]acetate Chemical compound CO\N=C(/C(=O)OC)C1=CC=CC=C1CO\N=C(/C)C1=CC=CC(C(F)(F)F)=C1 ONCZDRURRATYFI-QTCHDTBASA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 108091008819 oncoproteins Proteins 0.000 claims 1
- 102000027450 oncoproteins Human genes 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 102000016914 ras Proteins Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17053009P | 2009-04-17 | 2009-04-17 | |
| US61/170,530 | 2009-04-17 | ||
| PCT/US2010/031460 WO2010121180A1 (en) | 2009-04-17 | 2010-04-16 | Combination immunotherapy compositions against cancer and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014240182A Division JP2015044857A (ja) | 2009-04-17 | 2014-11-27 | 癌に対する併用免疫療法組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524075A JP2012524075A (ja) | 2012-10-11 |
| JP2012524075A5 true JP2012524075A5 (enExample) | 2013-06-13 |
| JP5759980B2 JP5759980B2 (ja) | 2015-08-05 |
Family
ID=42237003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505977A Active JP5759980B2 (ja) | 2009-04-17 | 2010-04-16 | 癌および感染症に対する免疫療法組成物の組み合わせ |
| JP2014240182A Withdrawn JP2015044857A (ja) | 2009-04-17 | 2014-11-27 | 癌に対する併用免疫療法組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014240182A Withdrawn JP2015044857A (ja) | 2009-04-17 | 2014-11-27 | 癌に対する併用免疫療法組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10383924B2 (enExample) |
| EP (2) | EP2419126B1 (enExample) |
| JP (2) | JP5759980B2 (enExample) |
| KR (2) | KR101781966B1 (enExample) |
| CN (1) | CN102458458B (enExample) |
| AU (1) | AU2010236206B2 (enExample) |
| CA (1) | CA2759013C (enExample) |
| ES (1) | ES2660597T3 (enExample) |
| MX (1) | MX2011010977A (enExample) |
| WO (1) | WO2010121180A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5570819B2 (ja) | 2007-02-02 | 2014-08-13 | グローブイミューン，インコーポレイテッド | 酵母を含む組成物および酵母を増殖させる方法 |
| EP2134358A1 (en) | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| EP2419126B1 (en) | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| AP2013007110A0 (en) | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| AU2012228937B2 (en) * | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
| BR112013032381B1 (pt) * | 2011-06-14 | 2021-01-12 | Globeimmune, Inc. | composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta |
| RU2017143985A (ru) * | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
| ES2525205T3 (es) | 2011-11-09 | 2014-12-18 | Werner Lubitz | Vacuna para su uso en inmunoterapia tumoral |
| WO2013148695A1 (en) * | 2012-03-27 | 2013-10-03 | Maida Iii Anthony E | Improved antitumor protocol |
| EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| EP2895191B1 (en) * | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
| WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| GB201217868D0 (en) * | 2012-10-05 | 2012-11-21 | Isis Innovation | Staphyolococcus aureus antigens |
| WO2014186047A1 (en) | 2013-03-19 | 2014-11-20 | Globeimmune, Inc. | Yeast-based immunotherapy for chordoma |
| WO2014160747A2 (en) | 2013-03-26 | 2014-10-02 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| KR101502680B1 (ko) * | 2013-04-01 | 2015-03-17 | 중앙대학교 산학협력단 | 난소과립종양세포 진단용 펩타이드 및 이의 용도 |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| WO2015123532A1 (en) * | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| KR102409372B1 (ko) * | 2014-04-11 | 2022-06-16 | 글로브이뮨 | 효모 면역 요법 및 타입 i 인터페론 감도 |
| US9753036B2 (en) * | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| JP6647315B2 (ja) * | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| KR102565284B1 (ko) | 2015-07-31 | 2023-08-08 | 버베리안 노딕 에이/에스 | 폭스바이러스에서 발현을 증강하기 위한 프로모터 |
| WO2017023840A1 (en) * | 2015-08-03 | 2017-02-09 | Globeimmune, Inc. | Modified yeast-brachyury immunotherapeutic compositions |
| EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
| AU2017217940B2 (en) * | 2016-02-12 | 2024-03-21 | Madison Vaccines Inc. | Cancer therapy |
| WO2017222619A2 (en) | 2016-03-24 | 2017-12-28 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
| AU2017304219A1 (en) * | 2016-07-25 | 2019-02-21 | Ascend Biopharmaceuticals Ltd | Methods of treating cancer |
| WO2018200389A1 (en) | 2017-04-24 | 2018-11-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| JP7202362B2 (ja) * | 2017-08-24 | 2023-01-11 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
| DE102017012109A1 (de) * | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| EP3824097A4 (en) * | 2018-07-22 | 2022-03-30 | Health Research, Inc. | MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II EXPRESSING CANCER CELL VACCINE AND METHODS OF USE FOR GENERATING INTEGRATED IMMUNE RESPONSES |
| CA3169984A1 (en) * | 2020-02-07 | 2021-08-12 | The Regents Of The University Of California | Methods and use for bioengineering enucleated cells |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| JP2023521837A (ja) * | 2020-04-14 | 2023-05-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 大きな配列の汎コロナウイルスワクチン組成物 |
| EP3957322A1 (en) * | 2020-08-19 | 2022-02-23 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Recombinant poxviridae vector expressing co-stimulatory molecules |
| CN113244273A (zh) * | 2021-03-16 | 2021-08-13 | 广州中科蓝华生物科技有限公司 | 疟原虫在制备联合放射疗法用于抗肿瘤的制剂中的应用 |
| WO2025207938A1 (en) * | 2024-03-29 | 2025-10-02 | University Of Washington | Nucleic acid vaccines against coccidioidomycosis |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1038392A (en) | 1912-04-17 | 1912-09-10 | Edmund P Kohn | Safety-catch for jewelry. |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| US20060121011A1 (en) * | 1988-03-21 | 2006-06-08 | Jolly Douglas J | Combination gene delivery vehicles |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
| EP0721341A4 (en) | 1993-08-06 | 1998-04-22 | Cytel Corp | CLONING AND DESCRIPTION OF FULL MAGE-1 GENE CHARACTERISTICS |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
| JP3907698B2 (ja) | 1994-10-03 | 2007-04-18 | アメリカ合衆国 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| ES2286530T3 (es) | 1997-10-10 | 2007-12-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Peptidos antagonistas del antigeno carcinoembrionario (cea). |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20070048860A1 (en) | 1997-10-10 | 2007-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Carcinoembryonic antigen (CEA) peptides |
| EP1137792B9 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| ES2260078T3 (es) | 2000-04-06 | 2006-11-01 | Seer Pharmaceuticals, Llc. | Sistema de administracion microbiana. |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| CN1635118A (zh) * | 2003-12-29 | 2005-07-06 | 吉林大学第一医院 | 人癌胚抗原肽表位基因编码序列串联体的合成及表位疫苗 |
| JP2007528375A (ja) * | 2004-03-02 | 2007-10-11 | 典也 大野 | 癌の治療および予防用雑種細胞ワクチンの方法および組成物 |
| AU2005295317B2 (en) * | 2004-10-18 | 2011-10-13 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20100034840A1 (en) | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| MX2008009929A (es) | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
| CN101448848B (zh) | 2006-03-27 | 2013-12-04 | 全球免疫股份有限公司 | Ras突变及其相关组合物和方法 |
| US20080171059A1 (en) | 2006-08-07 | 2008-07-17 | Shanshan Wu Howland | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens |
| JP5570819B2 (ja) | 2007-02-02 | 2014-08-13 | グローブイミューン，インコーポレイテッド | 酵母を含む組成物および酵母を増殖させる方法 |
| EP2134358A1 (en) | 2007-03-19 | 2009-12-23 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| EP2419126B1 (en) | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
-
2010
- 2010-04-16 EP EP10715632.5A patent/EP2419126B1/en active Active
- 2010-04-16 US US13/264,846 patent/US10383924B2/en active Active
- 2010-04-16 MX MX2011010977A patent/MX2011010977A/es active IP Right Grant
- 2010-04-16 EP EP17203871.3A patent/EP3320915A1/en active Pending
- 2010-04-16 CA CA2759013A patent/CA2759013C/en active Active
- 2010-04-16 ES ES10715632.5T patent/ES2660597T3/es active Active
- 2010-04-16 WO PCT/US2010/031460 patent/WO2010121180A1/en not_active Ceased
- 2010-04-16 KR KR1020117027319A patent/KR101781966B1/ko active Active
- 2010-04-16 KR KR1020177026393A patent/KR102019728B1/ko active Active
- 2010-04-16 JP JP2012505977A patent/JP5759980B2/ja active Active
- 2010-04-16 CN CN201080026166.0A patent/CN102458458B/zh active Active
- 2010-04-16 AU AU2010236206A patent/AU2010236206B2/en active Active
-
2014
- 2014-11-27 JP JP2014240182A patent/JP2015044857A/ja not_active Withdrawn
-
2019
- 2019-07-01 US US16/458,726 patent/US10874729B2/en active Active
-
2020
- 2020-11-18 US US16/951,739 patent/US11596675B2/en active Active
- 2020-12-22 US US17/130,551 patent/US11590216B2/en active Active
-
2023
- 2023-01-24 US US18/158,800 patent/US12076382B2/en active Active
-
2024
- 2024-07-05 US US18/764,645 patent/US20240350604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524075A5 (enExample) | ||
| JP2014509595A5 (enExample) | ||
| Vergati et al. | Strategies for cancer vaccine development | |
| JP2016537417A5 (enExample) | ||
| Sims | Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer | |
| Raez et al. | Lung cancer immunotherapy | |
| JP2007524613A5 (enExample) | ||
| JP2004507231A5 (enExample) | ||
| ATE421533T1 (de) | Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden | |
| Pawlik et al. | Malignant melanoma: current state of primary and adjuvant treatment | |
| JP2012021028A5 (enExample) | ||
| Bashir et al. | Immunotherapy regimens for metastatic colorectal carcinomas | |
| Baratta | Glioblastoma is ‘hot’for personalized vaccines | |
| He et al. | Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer | |
| McNeel | Therapeutic cancer vaccines: how much closer are we? | |
| WO2003085098A3 (en) | Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti | |
| Ramlogan-Steel et al. | Lung cancer vaccines: current status and future prospects | |
| Ahmad et al. | DNA vaccination for prostate cancer, from preclinical to clinical trials-where we stand? | |
| WO2021055580A3 (en) | An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use | |
| Qu et al. | A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity | |
| Fournier et al. | Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 | |
| Berraondo et al. | Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines | |
| Izzi et al. | Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains | |
| Powell et al. | BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer | |
| Curigliano et al. | Immunology and breast cancer: therapeutic cancer vaccines |